{
    "clinical_study": {
        "@rank": "46978", 
        "arm_group": {
            "arm_group_label": "3-Tesla magnetic resonance imaging", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in\n      measuring treatment response in patients with high-grade glioma. New diagnostic procedures,\n      such as advanced MRI techniques at 3 Tesla, may be more effective than standard MRI in\n      measuring treatment response in patients receiving treatment for high-grade gliomas."
        }, 
        "brief_title": "3T MRI Biomarkers of Glioma Treatment Response", 
        "condition": [
            "Adult Anaplastic Astrocytoma", 
            "Adult Anaplastic Ependymoma", 
            "Adult Anaplastic Oligodendroglioma", 
            "Adult Giant Cell Glioblastoma", 
            "Adult Glioblastoma", 
            "Adult Gliosarcoma", 
            "Recurrent Adult Brain Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Brain Neoplasms", 
                "Ependymoma", 
                "Glioblastoma", 
                "Oligodendroglioma", 
                "Gliosarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To correlate treatment-induced changes in quantitative MRI-based biomarkers\u2014specifically,\n      those sensitive to tumor protein content (amide proton transfer asymmetry [APTasym] from\n      chemical exchange saturation transfer [CEST]), cellularity (apparent diffusion coefficient\n      [ADC] from diffusion-weighted imaging [DWI]), and blood flow (volume transfer constant\n      [K^trans] from dynamic contrast-enhanced [DCE]; cerebral blood flow [CBF] from dynamic\n      susceptibility contrast [DSC])\u2014with treatment-induced changes in tumor size, measured via\n      standard anatomic MRI.\n\n      II. To correlate treatment-induced changes in the above quantitative MRI endpoints with\n      patient progression-free survival (PFS).\n\n      OUTLINE:\n\n      Patients undergo measurement of tumor protein content using CEST-MRI, cellularity using\n      DWI-MRI, and blood flow using DCE-MRI and DSC-MRI within 2 weeks of treatment and at 2 and 4\n      weeks after initiation of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must sign an institutional review board (IRB)-approved informed consent\n             document\n\n          -  Patients must have been diagnosed with high-grade glioma:\n\n               -  World Health Organization (WHO) grade III: anaplastic astrocytoma,\n                  oligodendroglioma, ependymoma, or oligoastrocytoma; OR\n\n               -  WHO grade IV: glioblastoma multiforme; or neuroepithelial tumors of uncertain\n                  origin (polar spongioblastoma, astroblastoma, or gliomatosis cerebri)\n\n          -  As measured by conventional high spatial resolution MRI, the minimum diameter of the\n             primary lesion (short axis) should be at least 5 mm\n\n          -  Patients must be scheduled to receive: 1) standard chemotherapy with/without\n             radiation therapy; OR 2) single-agent bevacizumab (Avastin)\n\n        Exclusion Criteria:\n\n          -  Patients with low-grade (WHO grade I or II) glioma\n\n          -  Patients with metastatic disease\n\n          -  Patients who have any type of bioimplant activated by mechanical, electronic, or\n             magnetic means (e.g., cochlear implants, pacemakers, neurostimulators,\n             biostimulators, electronic infusion pumps, etc), because such devices may be\n             displaced or malfunction\n\n          -  Patients who have any type of ferromagnetic bioimplant that could potentially be\n             displaced\n\n          -  Patients who have cerebral aneurysm clips\n\n          -  Patients who may have shrapnel imbedded in their bodies (such as from war wounds),\n             metal workers and machinists (potential for metallic fragments in or near the eyes)\n\n          -  Patients with inadequate renal function (creatinine >= 1.5 times upper limit of\n             normal) or acute or chronic renal insufficiency (glomerular filtration rate < 20\n             ml/min)\n\n          -  Patients who are pregnant or breast feeding; urine pregnancy test will be performed\n             on women of child bearing potential\n\n          -  Patients who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe\n             vertigo when they are moved into the magnet bore\n\n          -  Patients incapable of giving informed written consent, for the following reasons:\n\n               -  Inability to adhere to the experimental protocols for any reason\n\n               -  Inability to communicate with the research team\n\n               -  Limited ability to give informed consent due to mental disability, altered\n                  mental status, confusion, cognitive impairment, or psychiatric disorders\n\n                    -  Patients scoring 14.5 or lower on the University of California at San Diego\n                       (UCSD) Brief Assessment of Consent Capacity (UBACC) Capacity to Consent\n                       Questionnaire will be excluded\n\n               -  Prisoners or other individuals deemed to be susceptible to coercion\n\n          -  For patients who have undergone surgical resection prior to joining the study, in\n             whom baseline magnetic resonance (MR) images exhibit enough signal degradation (due\n             to susceptibility artifact in the region of the surgical bed) such that the data are\n             uninterpretable will be excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996527", 
            "org_study_id": "VICC NEU 1268", 
            "secondary_id": [
                "NCI-2013-02195", 
                "P30CA068485"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "3-Tesla magnetic resonance imaging", 
                "description": "3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI", 
                "intervention_name": "3-Tesla magnetic resonance imaging", 
                "intervention_type": "Device", 
                "other_name": [
                    "3-Tesla MRI", 
                    "3T MRI"
                ]
            }, 
            {
                "arm_group_label": "3-Tesla magnetic resonance imaging", 
                "description": "Undergo CEST-MRI", 
                "intervention_name": "CEST-MRI", 
                "intervention_type": "Device", 
                "other_name": "chemical exchange saturation transfer MRI"
            }, 
            {
                "arm_group_label": "3-Tesla magnetic resonance imaging", 
                "description": "Undergo DWI-MRI", 
                "intervention_name": "DW-MRI", 
                "intervention_type": "Device", 
                "other_name": "diffusion-weighted MRI"
            }, 
            {
                "arm_group_label": "3-Tesla magnetic resonance imaging", 
                "description": "Undergo DCE-MRI", 
                "intervention_name": "DCE-MRI", 
                "intervention_type": "Device", 
                "other_name": "dynamic contrast-enhanced MRI"
            }, 
            {
                "arm_group_label": "3-Tesla magnetic resonance imaging", 
                "description": "Undergo DSC-MRI", 
                "intervention_name": "DSC-MRI", 
                "intervention_type": "Device", 
                "other_name": "dynamic susceptibility contrast MRI"
            }, 
            {
                "arm_group_label": "3-Tesla magnetic resonance imaging", 
                "description": "Gadolinium-containing paramagnetic contrast agent (Magnevist\u00ae; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast", 
                "intervention_name": "IV administration of gadolinium-containing contrast agent", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Magnevist\u00ae", 
                    "gadopentetate dimeglumine"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 4, 2014", 
        "link": {
            "description": "Vanderbilt-Ingram Cancer Center, Find a Clinical Trial", 
            "url": "http://www.vicc.org/ct"
        }, 
        "location": {
            "contact": {
                "email": "chad.quarles@vanderbilt.edu", 
                "last_name": "Chad Quarles", 
                "phone": "615-322-6215"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37232"
                }, 
                "name": "Vanderbilt-Ingram Cancer Center"
            }, 
            "investigator": {
                "last_name": "Chad Quarles", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers", 
        "other_outcome": [
            {
                "description": "Evaluation of the following biological imaging metrics:\nAmide proton transfer asymmetry (APTasym) from CEST\nApparent diffusion coefficient (ADC) from DW-MRI\nVolume transfer constant (Ktrans), extravascular extracellular volume fraction (ve), and plasma volume fraction (vp) from DCE-MRI\nCerebral blood volume (CBV), cerebral blood flow (CBF) and mean transit time (MTT) from DSC-MRI Both conventional anatomic MRI and quantitative MRI sequences will be used in a single \"hybrid\" imaging exam to be conducted pre-treatment, early after treatment, and at a follow-up time point long", 
                "measure": "Changes in quantitative MRI-based biomarkers sensitive to tumor protein content, tumor perfusion and hemodynamics", 
                "safety_issue": "No", 
                "time_frame": "Baseline to within 4 weeks after on-treatment date"
            }, 
            {
                "description": "3T MRI techniques, that can supplement existing high-resolution anatomic imaging, will be performed to aid clinical decision-making for patients diagnosed with high-grade glioma. These techniques include:\nChemical Exchange Saturation Transfer (CEST)4\nDiffusion Weighted MRI (DWI, or DW-MRI)5,6\nDynamic Contrast Enhanced MRI (DCE-MRI)7\nDynamic Susceptibility Contrast MRI (DSC-MRI)8", 
                "measure": "Changes in quantitative MRI-based biomarkers using 3.0 Tesla (3T) biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline to within 4 weeks after on-treatment date"
            }
        ], 
        "overall_contact": {
            "last_name": "Vanderbilt-Ingram Clinical Trial Information Program", 
            "phone": "800-811-8480"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt-Ingram Cancer Center", 
            "last_name": "Chad Quarles", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients in each response category, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, summarized as follows for target lesion criteria:  complete response (CR),disappearance of target lesions; partial response (PR), >=30% decrease in sum of longest diameter (LD) of target lesions; progressive disease (PD), >=20% increase in sum of LD of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as either PD or SD. Patients are categorized according to the best response achieved prior to occurrence of progressive disease, where best response hierarchy is CR>PR>SD>PD.", 
            "measure": "Best Response", 
            "safety_issue": "No", 
            "time_frame": "On\u2010treatment date to date of disease progression (up to 12 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996527"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt-Ingram Cancer Center", 
            "investigator_full_name": "Chad Quarles", 
            "investigator_title": "Assistant Professor of Radiology and Radiological Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Estimated probable duration of life without disease progression, from on\u2010study date to earlier of progression date or date of death from any cause, using the Kaplan\u2010Meier method with censoring. Disease progression is defined under RECIST v1.1 as >=20% increase in sum of longest diameters (LD) of target lesions, unequivocal progression of non\u2010target lesions, or appearance of new lesions.", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "On\u2010study date to lesser of date of progression or date of death from any cause (assessed at 6 months)"
        }, 
        "source": "Vanderbilt-Ingram Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt-Ingram Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}